PPA
PHAS

Parametric Portfolio Associates’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Parametric Portfolio Associates’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,254
Closed -$38K – 3700
2021
Q2 		$38K Buy
+10,254
New +$34.1K ﹤0.01% 3547
2020
Q3 		– Sell
-20,066
Closed -$92K – 3995
2020
Q2 		$92K Buy
+20,066
New +$88.9K ﹤0.01% 3799

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Parametric Portfolio Associates's PHAS Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2021, closing a stake of 10,254 shares — an estimated $38K sold.

Parametric Portfolio Associates first reported a position in PHAS in Q2 2020 and held it in 2 quarters. The position peaked at $92K in Q2 2020. 61 funds tracked by Wall St. Rank hold PHAS as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 10,254 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $38K.
  • Parametric Portfolio Associates first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Parametric Portfolio Associates's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $92K in Q2 2020.
  • 61 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.